Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.

Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.

Bortezomib has been successful for treatment of multiple myeloma, but not against solid tumors, and toxicities of neuropathy, thrombocytopenia and the emergence of resistance have triggered efforts to find alternative proteasome inhibitors. Bis-benzylidine piperidones such as RA190 covalently bind A...

Full description

Bibliographic Details
Main Authors: Ravi K Anchoori, Vidyasagar Anchoori, Brandon Lam, Ssu-Hsueh Tseng, Samarjit Das, Fernanda Carrizo Velasquez, Balasubramanyam Karanam, Deepika Poddatoori, Ramesh Patnam, Michelle A Rudek, Yung-Nien Chang, Richard B S Roden
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0285221

Internet

https://doi.org/10.1371/journal.pone.0285221

Similar Items